CIK 0002056611 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Latigo Biotherapeutics, Inc.
Sign in to watch- Ticker
- LTGO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 832625838
- Phone
- 805-716-2927
- Business address
- 1300 RANCHO CONEJO BLVD., SUITE 305, THOUSAND OAKS, CA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-10 | Westlake BioPartners Fund I, L.P. 10% owner | Conversion · Series A-2 Convertible Preferred Stock | −3,464,072 | 0 | ||
| 2026-08-10 | Westlake BioPartners Fund I, L.P. 10% owner | Conversion · Series B Convertible Preferred Stock | −1,484,401 | 0 | ||
| 2026-08-10 | Westlake BioPartners Fund I, L.P. 10% owner | Conversion · Series A-2 Convertible Preferred Stock | −2,066,857 | 0 | ||
| 2026-08-10 | Westlake BioPartners Fund I, L.P. 10% owner | Conversion · Convertible Promissory Note | −165,519 | 0 | ||
| 2026-08-10 | Tananbaum James B. Director | Conversion | +3,117,664 | 3,117,664 | ||
| 2026-08-10 | Tananbaum James B. Director | Conversion | +445,320 | 3,562,984 | ||
| 2026-08-10 | Tananbaum James B. Director | Conversion | +1,125,823 | 1,125,823 | ||
| 2026-08-10 | Tananbaum James B. Director | Conversion | +742,201 | 1,868,024 | ||
| 2026-08-10 | Tananbaum James B. Director | Purchase | +140,000 | $18.00 | $2.5M | 2,008,024 |
| 2026-08-10 | Tananbaum James B. Director | Conversion | +195,776 | 2,203,800 | ||
| 2026-08-10 | Tananbaum James B. Director | Conversion | +3,117,664 | 3,117,664 | ||
| 2026-08-10 | Tananbaum James B. Director | Conversion | +296,880 | 3,414,544 | ||
| 2026-08-10 | Tananbaum James B. Director | Conversion · Series A-2 Convertible Stock | −3,117,664 | 0 | ||
| 2026-08-10 | Tananbaum James B. Director | Conversion · Series B Convertible Preferred Stock | −445,320 | 0 | ||
| 2026-08-10 | Tananbaum James B. Director | Conversion · Series A-2 Convertible Preferred Stock | −1,125,823 | 0 | ||
| 2026-08-10 | Tananbaum James B. Director | Conversion · Series B Convertible Preferred Stock | −742,201 | 0 | ||
| 2026-08-10 | Tananbaum James B. Director | Conversion · Series A-2 Convertible Preferred Stock | −3,117,664 | 0 | ||
| 2026-08-10 | Tananbaum James B. Director | Conversion · Series B Convertible Preferred Stock | −296,880 | 0 | ||
| 2026-08-10 | Tananbaum James B. Director | Conversion · Convertible Promissory Note | −195,776 | 0 | ||
| 2026-08-10 | SEIDENBERG BETH C Director | Conversion | +938,979 | 1,368,532 |
Page 2 of 4 · 69 trades